AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05707650 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: reverse breech extraction technique or push technique
Description: using reverse breech extraction technique or push technique for disimpaction of fetal head during cs of a fully dilated cervix
Study NCT04808687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel and S-1
Description: Nab-Paclitaxel: 125 mg/m2 d1, 8, during each 3-week cycle. S-1: Body surface area \< 1.25 m2, 40 mg bid; Body surface area ≥ 1.25 m2 \< 1.50 m2, 50 mg bid; Body surface area ≥1.5 m2, 60 mg bid, d1-14;during each 3-week cycle.
Study NCT05288088 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: No intervention
Description: This is an observational study
Study NCT05330520 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Butterfly Medical Prostatic Retraction Device (the Butterfly device) removal/replacement
Description: when necessary, the device may be removed or replaced easily through the urethra due to its minimal surface and easy release from the mucosa covering it.
Study NCT05153382 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical behavioral therapy
Description: DBT will be conducted over 1 year, and divided into two modalities: skills training, conducted in 60 minute biweekly meetings and individual therapy conducted in 60 minute biweekly sessions. Family participation in skills training is highly encouraged. Skills training proceeds as follows: psychoeducation, mindfulness skills, emotion regulation skills, distress tolerance skills, interpersonal skills, and walking the middle path skills. Individual therapy sessions aim to aid the youth in applying skills in their daily lives. We adopt the standard DBT hierarchy of treatment targets, whereby the individual therapist selects behaviors to focus on based on the following priorities: 1) decreasing life-threatening behaviors, 2) decreasing therapy-interfering behaviors, 3) decreasing quality-of-life interfering behaviors, and 4) increasing behavioral skills. Therapists will be available to participants by cell phone for in-vivo skills coaching between sessions.
Study NCT05614011 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: RT-PCR Test
Description: High sensitivity RT-PCR COVID-19 Test. A healthcare professional will take a sample per subject for the comparator test, following the manufacturer's Instructions For Use (IFU) in one nostril.
Study NCT05614011 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Real-time PCR Test
Description: Mid-turbinate nasal swab samples will be taken from the opposite nostril that was not swabbed for the comparator sample using Copan FLOQ swabs and placed into MSwab buffer. In instances where opposite nostrils cannot be swabbed for both the comparator and the candidate tests, a 15-minute waiting period to allow for viral reloading will occur before collecting the candidate test sample.
Study NCT05742620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anlotinib+CAPEOX/SOX
Description: Patients with colorectal cancer use the anlotinib+CAPEOX protocol, and patients with gastric cancer use the anlotinib+SOX protocol.~Anlotinib: 12mg, administered once a day on day 1-14, taken about half an hour before breakfast (the time of daily administration should be the same as much as possible), delivered with warm water, repeated once every three weeks;~CAPEOX: capecitabine 1000mg/m2 each time, oral, twice a day, 1-14 days; Oxaliplatin: 130mg/m2 iv drip d1.~SOX: Tegio: 100mg/day, continuous medication for 2 weeks, stop for 1 week; Oxaliplatin: 130mg/m2 iv drip d1.
Study NCT05749588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A1: SHR-A1811
Description: A1: an anti-HER2 antibody-drug conjugate (ADC)
Study NCT05749588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A2: SHR-A1811 with Camrelizumab
Description: A2: SHR-A1811: an anti-HER2 antibody-drug conjugate (ADC)~Camrelizumab: an anti-programmed death-1 (PD-1) antibody
Study NCT06293586 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peribulbar block
Description: Peribulbar block using a two-injection technique was performed by a second anesthetist under sterile conditions and before the application of surgical drapes. LAM was injected both infratemporal and superonasally using a 26-G needle, in contrast to the single infratemporal injection approach.~Gentle digital oculopression was performed for 5 minutes
Study NCT05749588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B1: TROP2 ADC
Description: B1: an Trophoblast cell-surface antigen 2 (TROP2) ADC
Study NCT05749588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B2: TROP2 ADC with Camrelizumab
Description: B2: TROP2 ADC : an Trophoblast cell-surface antigen 2 (TROP2) ADC~Camrelizumab: an anti-programmed death-1 (PD-1) antibody
Study NCT05749588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C1: SHR-A1811
Description: C1: an anti-HER2 antibody-drug conjugate (ADC)
Study NCT05749588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C2: SHR-A1811 with BP102
Description: C2: SHR-A1811: an anti-HER2 antibody-drug conjugate (ADC)~BP102: a humanized recombinant monoclonal IgG1 antibody (biosimilar to bevacizumab)
Study NCT05749588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D1: TROP2 ADC
Description: D1: an Trophoblast cell-surface antigen 2 (TROP2) ADC
Study NCT05749588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D2: TROP2 ADC with BP102
Description: D2: TROP2 ADC : an Trophoblast cell-surface antigen 2 (TROP2) ADC~BP102: a humanized recombinant monoclonal IgG1 antibody (biosimilar to bevacizumab)
Study NCT05749588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E1: SHR-A1811
Description: E1: an anti-HER2 antibody-drug conjugate (ADC)
Study NCT05749588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F1: TROP2 ADC
Description: F1: an Trophoblast cell-surface antigen 2 (TROP2) ADC
Study NCT06293586 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sub-tenon block
Description: Children in the sub-Tenon group received a sub-Tenon block. Sub-Tenon's anesthesia was performed with 0.5% bupivacaine (0.08 ml/kg), bearing in mind not to exceed the maximum dose. Under sterile conditions, a 19- gauge curved blunt metallic cannula (25 mm) was inserted into sub-Tenon's space and the local anesthetic was injected by the ophthalmologist after the application of surgical drapes.
Study NCT06293586 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Children in the control group received IV paracetamol (15 mg/kg) after induction of anesthesia before any surgical intervention.
Study NCT05824481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: Injectable solution
Study NCT05824481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Capsule
Study NCT04673721 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fortified eggs
Description: Average 12 eggs consumed per week
Study NCT04673721 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent fasting
Description: 16-hour fast and then an 8-hour nutritional window with aim for energy needs to be consumed during an 8 hour eating window (e.g., 11 am - 7 pm) with fasting for 16 hours (e.g., 7 pm - 11 am the next day).
Study NCT04673721 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Non-egg supplemented
Description: 2 or less eggs consumed per week
Study NCT04673721 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Non-egg supplemented
Description: 2 or less eggs consumed per week
Study NCT04673721 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care diet
Description: Consistency with current diet without consideration of intermittent fasting
Study NCT04673721 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual care diet
Description: Consistency with current diet without consideration of intermittent fasting
Study NCT06385236 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Dupilumab
Description: Dupilumab, an interleukin-4 receptor treatment, will be administered through a subcutaneous injection, the initial dose of 600 mg will be administered at two different injection sites (300 mg per injection), followed by a single dose of 300 mg administered every other week (Q2W).~Participants may self-administer injection after proper training.
Study NCT06385236 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Benralizumab
Description: Benralizumab, an interleukin-5 receptor treatment, will be administered through a subcutaneous injection every 4 weeks (Q4W).~Participants may self-administer injection after proper training.
Study NCT05613686 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation
Description: Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technology. High and low frequencies of rTMS could modulate the excitability of the cerebral cortex. Theta burst stimulation (TBS) has achieved a similar effect to traditional rTMS mode. Intermittent TBS (iTBS) could upregulate cortical excitability of the primary motor cortex (M1) and continuous TBS (cTBS) with inhibitory effect.
Study NCT05613686 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation
Description: Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technology. High and low frequencies of rTMS could modulate the excitability of the cerebral cortex. Theta burst stimulation (TBS) has achieved a similar effect to traditional rTMS mode. Intermittent TBS (iTBS) could upregulate cortical excitability of the primary motor cortex (M1) and continuous TBS (cTBS) with inhibitory effect.
Study NCT06244043 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Initial Coaching Call
Description: Participant will receive initial coaching call with a team member. This coaching call will either be interventional (i.e., include content intended to prompt their adherence and benefit from the HMP app) or informational (i.e., include content intended to control for the time and attention of attending a coaching session, but not intended to provide specific benefits).
Study NCT06244043 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Email Support
Description: Email-based support throughout study period
Study NCT06244043 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Text Messages
Description: All participants with receive text messages encouraging them to engage in the practices taught in the app.
Study NCT05520567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Oral
Study NCT06560528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combination with Disitamab Vedotin and with Tislelizumab and Capecitabine
Description: Subjects will receive Disitamab Vedotin combined with Tislelizumab and Capecitabine for 3 cycles (Q3W) in the neoadjuvant phase and 5 cycles (Q3W) of treatment in the adjuvant phase.~1. Disitamab Vedotin：2.5 mg/kg，Q3W；~2. Tislelizumab：200 mg，Q3W；~3. Capecitabine：1000 mg /m2, PO, bid d1-14, Q3W.
Study NCT06476977 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dorsal webspace combined corticosteroid and anesthetic injection
Description: The dorsal webspace injection consists of a 1cc mixture of 0.5cc triamcinolone (Kenalog) 10mg/mL and 0.5cc 1% lidocaine for analgesic purposes.
Study NCT06476977 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Palmar combined corticosteroid and anesthetic injection
Description: The palmar injection consists of a 1cc mixture of 0.5cc triamcinolone (Kenalog) 10mg/mL and 0.5cc 1% lidocaine for analgesic purposes.
Study NCT05012254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Patients will receive Ipilimumab 1mg/Kg administered by IV infusion every 42 days (Q6W) until disease progression, unacceptable toxicity, loss of clinical benefit as judged by the investigator or up to a maximum of 2 years of treatment.~Structure: is a fully human monoclonal antibody with two heavy chains and two kappa light chains linked together by way of disulfide bonds. The molecular weight is approximately 148 kDa and it exists in solution at a physiologic pH of 7.0.~Route of administration: Intravenous infusion.
Study NCT05012254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Patients will receive Nivolumab 360 mg administered by IV infusion every 21 days (Q3W) until disease progression, unacceptable toxicity, loss of clinical benefit as judged by the investigator or up to a maximum of 2 years of treatment.~Structure: Nivolumab is a soluble protein consisting of 4 polypeptide chains, which include 2 identical heavy chains and 2 identical light chains.~Route of administration: Intravenous infusion.
Study NCT05012254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Patients will receive Carboplatin AUC 5 or 6 administered by IV infusion every 21 days (Q3W), for 2 cycles.~Structure: The cis-diamino (cyclobutane-1, 1 dicarboxylate) platin. Stability: 24 hours at ambient temperature in 5% glucose, glucosa or physiologic saline. It is recommended not to dilute with chlorinated solutions since this could affect the carboplatin.~Route of administration: Intravenous infusion. Guidelines of Carboplatin administration: According to the standard of each center.
Study NCT05012254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Patients will receive Cisplatin 75mg/m2 administered by IV infusion every 21 days (Q3W), for 2 cycles.~Structure: (CAS No. 15663-27-1, MF-Cl2H6N2Pt; NCF-119875), cisplatinum, also called cis-diamminedichloroplatinum(II), is a metallic (platinum) coordination compound with a square planar geometry. It is a white or deep yellow to yellow-orange crystalline powder at room temperature.~Stability: Do not store above 25°C. Do not refrigerate or freeze. Keep container in the outer carton to protect from light. Following dilution in 0.9% sodium chloride injection, chemical and physical in-use stability has been demonstrated for up to 14 days at 20°C.~Route of administration: Intravenous infusion. Guidelines of Cisplatin administration: According to the standard of each center.
Study NCT05012254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Patients will receive Paclitaxel 200mg/m2 administered by IV infusion every 21 days (Q3W), for 2 cycles.~Structure: A diterpene whose composition is: 5b, 20-epoxy-1, 2a, 4,7b, 10b, 13a-hexahidroxytax-11-en 9 one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)- N-benzoyl-3-phenylisoserine.~Stability: Concentrations of 0.3-1.2 mg/ml in 5% dextrose or normal saline have demonstrated chemical and physical stability for more that 27 hours at ambient temperature (25ºC approximately). The intact vial must be stored between 15º and 25ºC.~Guidelines of Paclitaxel administration: Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml.
Study NCT05012254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Patients will receive Pemetrexed 500mg/m2 administered by IV infusion every 21 days (Q3W), for 2 cycles.~Structure: Pemetrexed disodium (ALIMTA®, pemetrexed) is a novel pyrrol \[2,3 d\]-pyrimidine based folic acid analogue.~Route of administration: Intravenous infusion. Guidelines of Pemetrexed administration: According to the standard of each center
Study NCT05520567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral
Study NCT06133920 — intervention group
Intervention type: OTHER
Intervention: Early Range of Motion
Description: The early range of motion group will be given a sling for comfort after their surgery. They will be told they can use their arm as tolerated and can remove the sling when comfortable immediately after surgery. They will be allowed to start passive range of motion, active assisted range of motion, and gentle active range of motion with therapy as tolerated with the exception of no internal rotation. They will also not be allowed to strengthen until 12 weeks after surgery. They will get formal physical therapy and be given a home exercise program as well that will be directed by their physical therapist
Study NCT06133920 — intervention group
Intervention type: OTHER
Intervention: Immobilization
Description: The immobilization group will be placed in a shoulder abduction sling immediately after surgery for four weeks. They will be allowed to start gentle passive range of motion with forward flexion to 120 degrees, abduction to 90 degrees, and external rotation to 30 degrees. They will receive a home exercise program and formal physical therapy with these limits.~When they come out of the sling at four weeks they will start active range of motion and active assisted range of motion. They cannot internally rotate until 10 weeks after surgery. No formal strengthening until 3 months after surgery.
Study NCT06429540 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Partially Demineralized Dentin Block
Description: The extracted tooth will be dried using air, then ground and partially demineralized with the Tooth Transformer device following the manufacturer's protocol. Dentin particles will be obtained with dimensions of 400-800 μm. The partially demineralized dentin will then be prepared by cutting the Leukocyte-Platelet Rich Fibrin (L-PRF) membranes into small pieces and mixing them with the dentin particles. Liquid fibrinogen will be added to the homogeneous mixture. Within a few minutes, the fibrinogen will convert into fibrin primarily from the activated blood platelets in the chopped L-PRF membranes. This process will effectively trap the biomaterial and the L-PRF pieces, forming the dentin block. After that, the sockets will be carefully packed with the dentin block and it will be covered with L-PRF membrane. To ensure stability and prevent displacement, the wounds will be secured using non-resorbable sutures.
Study NCT06429540 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Xenograft
Description: In the control group using the Xenograft, the same extraction and socket debridement procedure will be performed. Following that, the extraction socket will be thoroughly filled with deproteinized bovine bone mineral, and a collagen membrane will be employed to cover the socket. The membrane will be shaped to extend 2-3 mm beyond the margins of the extraction socket and positioned just beneath the marginal mucosa. To ensure its stability, a cross-suture will be performed, securing the membrane in place.
Study NCT06562387 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Description: Transcranial direct current stimulation is one of the most studied techniques in noninvasive neuromodulation. With a very good safety profile and low cost, it has been widely used to modulate cognition and behavior in both experimental and clinical settings. A growing body of literature, including randomized controlled trials, reports the clinical benefits of tDCS for many psychiatric symptoms, such as depression, anxiety, psychosis, addiction, and cognitive functions. tDCS has considerable potential as a treatment due to its relative cost, portability, safety, and ease of use compared to other neuromodulation methods. Early studies evaluated the effects of tDCS on the motor cortex; however, more recent research has also focused on its effects on the dorsolateral prefrontal cortex (DLPFC), in particular for treating psychiatric disorders and modulating cognitive performance.
Study NCT06562387 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cognitive stimulation
Description: This brain stimulation program is based on cognitive reserve and neuronal plasticity to improve mental performance through online games. The activities presented in this tool combine different therapeutic exercises, rehabilitation and learning techniques aimed at retraining and improving the skills most needed by each person. The intervention battery has multi-disciplinary tasks organized in a systematic and strategic way. To make these materials accessible, they are presented in the form of simple games that can be easily practiced through any computer or device. These cognitive stimulation tools are aimed at both healthy subjects and people concerned about their brain health, or patients with some kind of injury or decline in the central nervous system.
Study NCT06562387 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: cognitive stimulation
Description: This brain stimulation program is based on cognitive reserve and neuronal plasticity to improve mental performance through online games. The activities presented in this tool combine different therapeutic exercises, rehabilitation and learning techniques aimed at retraining and improving the skills most needed by each person. The intervention battery has multi-disciplinary tasks organized in a systematic and strategic way. To make these materials accessible, they are presented in the form of simple games that can be easily practiced through any computer or device. These cognitive stimulation tools are aimed at both healthy subjects and people concerned about their brain health, or patients with some kind of injury or decline in the central nervous system.
Study NCT06562387 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham transcranial direct current stimulation
Description: Regarding the simulated condition or sham, the equipment has the option inside to program it. It gives the options: Active / sham protocol, by default: ON - enables active stimulation and OFF - enables sham stimulation. The devices will be programmed, such that a few seconds of stimulation are administered at the beginning and end of the programmed time period to mimic the cutaneous perceptions (itching, tingling) that tend to be reported within the first few moments of stimulator on, without being able to modify cortical excitability.